The Latest Clinical Data of Cellular Matrix® Technology in Dermatology

一月 4, 2018

RegenLab SA Presents The Latest Clinical Data on the Use of Cellular Matrix® Technology in Dermatology, Mixing the Patient's Platelet Rich Plasma with Hyaluronic Acid in a One-Step Closed System

The Journal of American Academy of Dermatology recently published "The Efficacy of Autologous platelet-rich plasma combined with hyaluronic acid on skin facial rejuvenation: A prospective study" by Hersant B, SidAhmed-Mezi M, Niddam J, La Padula S, Noel W, Ezzedine K, Rodriguez AM, Meningaud JP.

Through published clinical studies, Cellular Matrix technology has gained acceptance in the field of Musculoskeletal Pain Management, in particular for the treatment of Knee Osteoarthritis.

CellularMatrix is a Class III medical device cleared for marketing in Europe (EC Marked), and key Middle East, North African, Asian, and Latin American Markets. These products are not cleared by the U.S. FDA for sale in the USA.

Released Patents:

- For the preparation of Platelet Rich Plasma in tubes with a thixotropic separator gel: U.S. patent US8529957, European patent EP2073862B, (...)

- On the CellularMatrix Technology, for the preparation of Platelet Rich Plasma mixed with Hyaluronic Acid in tubes: U.S. patent US8945537, U.S. patent US9517255, European patent EP2544697B1, Canada, PR. China, Australia, Japan, Russia, Israel, (...)

Regen Lab enforces its intellectual property rights worldwide. It has already filed numerous intellectual property lawsuits in Europe, People's Republic of China and the United States of America